Cyclodextrin-based controlled drug release system

Advanced Drug Delivery Reviews

Volumn 36, Issue 1, 1999, Pages 125-141

  Hirayama, F ^a   Uekama, K ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Colon targeting; Controlled release; Cyclodextrin; Drug carrier; Drug cyclodextrin conjugate; Inclusion complex; Oral drug delivery

Indexed keywords

COMPLEXATION; CONTROLLED DRUG DELIVERY; DRUG DOSAGE; DRUG PRODUCTS;

CYCLODEXTRINS; DRUG CARRIERS; INCLUSION COMPLEXES;

POLYSACCHARIDES;

CYCLODEXTRIN DERIVATIVE; DILTIAZEM; NIFEDIPINE;

COMPLEX FORMATION; CONJUGATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0033104290     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00058-1     Document Type: Review

References (107)

1. R.L. Juliano (Ed.), Drug Delivery System, Oxford University Press, New York, 1980.
2. P. Buri, A. Gumma (Eds.), Drug Targeting, Elsevier, Amsterdam, 1985.
3. M. Szycher (Ed.), High Performance Biomaterials, A Comprehensive Guide to Medical and Pharmaceutical Applications, Technomic Publishing, PA, 1991.
4. J. Szejtli (Ed.), Cyclodextrins and their Inclusion Complexes, Academia Kiado, Budapest, 1982.
5. D. Duchêne (Ed.), Cyclodextrins and their Industrial Uses, Editions de Santé, Paris, 1987.
6. J. Szejtli (Ed.), Cyclodextrin Technology, Kluwer, Dordrecht, 1988.
7. K. Uekama, Pharmaceutical applications of cyclodextrin complexations, Yakugaku Zasshi 101 (1981) 857-873.
8. J. Pitha, L. Szente, J. Szejtli, Molecular encapsulation of drugs by cyclodextrins and congeners, in: S.D. Bruck (Ed.), Controlled Drug Delivery, Vol. I, CRC Press, Boca Raton, FL, 1983, Ch. 5.
9. D. Duchêne (Ed.), New Trends in Cyclodextrins and Derivatives, Editions de Santé, Paris, 1991.
10. K. Uekama, M. Otagiri, Cyclodextrins in drug carrier systems, CRC Crit. Rev. Ther. Drug Carrier Syst. 3 (1987) 1-40.
11. M.E. Brewster, W.R. Anderson, K.S. Estes, N. Bodor, Development of aqueous parenteral formulations for carbamazepine through the use of modified cyclodextrins, J. Pharm. Sci. 80 (1991) 380-383.
12. K. Uekama, T. Irie, Pharmaceutical use of cyclodextrins in various drug formulations, in: J. Szejtli, T. Osa (Eds.), Cyclodextrins. Comprehensive Supramolecular Chemistry, Vol. 3, Pergamon, Oxford, 1996.
13. K.-H. Frömming, J. Szejtli (Eds.), Cyclodextrins in Pharmacy, Kluwer, Dordrecht, 1994.
14. K. Uekama, F. Hirayama, T. Irie, Application of cyclodextrins. Drug absorption enhancement: concepts, possibilities, limitations and trends, in: A.G. Boer (Ed.), Drug Targeting Delivery, Vol. 3, Harwood Academic, Swizerland, 1994, pp. 411-456.
15. E. Albers, B.W. Müller, Cyclodextrin derivatives in pharmaceutics, CRC Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 311-337.
16. V.J. Stella, R.A. Rajewski, Cyclodextrins: their future in drug formulation and delivery, Pharm. Res. 14 (1997) 556-567.
17. D.O. Thompson, Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals, CRC Crit. Rev. Ther. Drug Carrier Syst. 14 (1997) 1-104.
18. T. Loftsson, M.E. Brewster, Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization, J. Pharm. Sci. 85 (1996) 1017-1025.
19. R.A. Rajewski, V.J. Stella, Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery, J. Pharm. Sci. 85 (1996) 1142-1169.
20. T. Irie, K. Uekama, Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation, J. Pharm. Sci. 86 (1997) 147-162.
21. K. Uekama, F. Hirayama, T. Irie, Cyclodextrin drug carrier systems, Chem. Rev. 98 (1998) 2045-2076.
22. J. Pitha, J. Pitha, Amorphous water-soluble derivatives of cyclodextrins, nontoxic dissolution enhancing excipients, J. Pharm. Sci. 74 (1985) 987-990.
23. B.W. Müller, U. Brauns, Solubilization of drugs by modified β-cyclodextrins, Int. J. Pharm. 26 (1985) 77-88.
24. A. Yoshida, H. Arima, K. Uekama, J. Pitha, Pharmaceutical evaluation of hydroxyalkylethers of β-cyclodextrins, Int. J. Pharm. 46 (1988) 217-222.
25. M.E. Brewster, J.W. Simpkins, M.S. Hora, W. Stern, N. Bodor, The potential use of cyclodextrins in parenteral formulations, J. Parent. Sci. Technol. 43 (1989) 231-240.
26. K. Koizumi, T. Utamura, M. Sato, Y. Yagi, Isolation and characterization of branched cyclodextrins, Carbohydr. Res. 153 (1986) 55-67.
27. M. Yamamoto, A. Yoshida, F. Hirayama, K. Uekama, Some physicochemical properties of branched β-cyclodextrins and their inclusion characteristics, Int. J. Pharm. 49 (1989) 163-171.
28. K. Uekama, Y. Horiuchi, T. Irie, F. Hirayama, O-Carboxymethyl-O-ethyl-cyclomaltoheptaose as a delayed-release-type drug carrier. Improvement of the oral bioavailability of diltiazem, Carbohydr. Res. 192 (1989) 323-330.
29. Y. Horiuchi, F. Hirayama, K. Uekama, Improvement, of stability and bioavailability of 1-hexylcarbamoyl-5-fluorouracil (HCFU) by O-carboxymethyl-O-ethyl-β-cyclodextrin, Yakugaku Zasshi 111 (1991) 592-599.
30. Y. Horiuchi, K. Abe, F. Hirayama, K. Uekama, Release control of theophylline by β-cyclodextrin derivatives: hybridizing effect of hydrophilic, hydrophobic and ionizable β-cyclodextrin complexes, J. Control. Release 15 (1991) 177-183.
31. 1 in hairless mice, Eur. J. Pharm. Sci. 1 (1993) 117-123.
32. F. Hirayama, Development and pharmaceutical evaluation of hydrophobic derivatives as modified-release drug carrier, Yakugaku Zasshi 113 (1993) 425-437.
33. K. Uekama, N. Hirashima, H. Horiuchi, F. Hirayama, T. Ijitsu, M. Ueno, Ethylated β-cyclodextrins as hydrophobic drug carriers: sustained release of diltiazem in the rat, J. Pharm. Sci. 76 (1987) 660-661.
34. F. Hirayama, M. Kurihara, Y. Horiuchi, T. Utsuki, K. Uekama, M. Yamasaki, Preparation of heptakis(2,6-di-O-ethyl)-β-cyclodextrin and its nuclear magnetic resonance spectroscopic characterization, Pharm. Res. 10 (1993) 208-213.
35. K. Uekama, H. Arima, T. Irie, K. Matsubara, K. Kuriki, Sustained release of buserelin acetate, a luteinizing hormone-releasing hormone agonist, from the injectable oily preparation utilizing ethylated β-cyclodextrin, J. Pharm. Pharmacol. 41 (1989) 874-876.
36. F. Hirayama, M. Yamanaka, T. Horikawa, K. Uekama, Characterization of peracylated β-cyclodextrins with different chain lengths as a novel sustained release carrier for water-soluble drugs, Chem. Pharm. Bull. 43 (1995) 130-136.
37. K. Matsubara, T. Irie, K. Uekama, Controlled-release of the LHRH agonist buserelin acetate from injectable suspensions containing triacetylated cyclodextrins in an oil vehicle, J. Control. Release 31 (1994) 173-180.
38. K. Uekama, F. Hirayama, Improvement of drug properties by cyclodextrins, in: C.G. Wermuth (Ed.), The Practice of Medicinal Chemistry, Academic Press, London, 1996, Ch. 37, pp. 793-825.
39. J.J. Marshall, I. Miwa, Kinetic difference between hydrolyses of γ-cyclodextrin by human salivary and pancreatic α-amylases, Biochim. Biophys. Acta 661 (1981) 142-147.
40. F. Hirayama, M. Yamamoto, K. Uekama, Acid-catalyzed hydrolysis of maltosyl-β-cyclodextrin, J. Pharm. Sci. 81 (1992) 913-916.
41. M. Yamamoto, H. Aritomi, T. Irie, F. Hirayama, K. Uekama, Biopharmaceutical evaluation of maltosyl-β-cyclodextrin as a parenteral drug carrier, S.T.P. Pharma Sci. 1 (1991) 397-402.
42. A-amino-[(4-biphenylyl)-acetyl]-α-, β-, and γ-cyclodextrins: potential prodrugs for colon-specific delivery, J. Med. Chem. 40 (1997) 2755-2761.
43. T. Tokumura, M. Nambu, Y. Tsushima, K. Tatsuishi, M. Kayano, Y. Machida, T. Nagai, Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with D,L-phenylalanine as a competing agent, J. Pharm. Sci. 75 (1986) 391-394.
44. K. Nakanishi, M. Masada, T. Nadai, K. Miyajima, Effect of the interaction of drug-β-cyclodextrin complex with bile salts on the drug absorption from rat small intestinal lumen, Chem. Pharm. Bull. 37 (1989) 211-214.
45. M.T. Esclusa-Diaz, M. Gayo-Otero, M.B. Perez-Marcos, J.L. Vila-Jato, J.J. Torres Labandeira, Preparation and evaluation of ketoconazole-β-cyclodextrin multicomponent complexes, Int. J. Pharm. 142 (1996) 183-187.
46. M. Pedersen, S. Bjerregaard, J. Jacobson, A.R. Larsen, A.M. Sorensen, An econazole β-cyclodextrin inclusion complex: an unusual dissolution rate, supersaturation, and biological efficacy example, Int. J. Pharm. 165 (1998) 57-68.
47. S. Hirai, H. Koyama, T. Makino, N. Kitamori, H. Toguchi, Formulation studies of a new oral cephalosporin, cefotiam hexetil hydrochloride [SCE-2174 (2HCl)], Yakuzaigaku 48 (1988) 189-196.
48. K. Uekama, T. Fujinaga, F. Hirayama, M. Otagiri, M. Yamasaki, H. Seo, T. Hashimoto, M. Tsuruoka, Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation, J. Pharm. Sci. 72 (1983) 1338-1341.
49. C.J. Betlach, M.A. Gonzalez, B.C. Mckiernan, C. Neff-Davis, N. Bodor, Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex, J. Pharm. Sci. 82 (1993) 1058-1060.
50. 1 by maltosyl-β-cyclodextrin in lyophilized formulation, Chem. Pharm. Bull. 40 (1992) 747-751.
51. T. Järvinen, K. Järvinen, N. Schwarting, V.J. Stella, β-Cyclodextrin derivatives, SBE-β-CD and HB-β-CD, increase the oral bioavailability of cinnarizine in beagle dogs, J. Pharm. Sci. 84 (1995) 295-299.
52. F. Hirayama, M. Usami, K. Kimura, K. Uekama, Crystallization and polymorphic transition behavior of chloramphenicol palmitate in 2-hydroxypropyl-β-cyclodextrin matrix, Eur. J. Pharm. Sci. 5 (1997) 23-30.
53. O.A. Soliman, K. Kimura, F. Hirayama, K. Uekama, H.M. El-Sabbagh, A.H. Abd ElGawad, F.M. Hashim, Amorphous spironolactone-hydroxypropylated cyclodextrins with superior dissolution and oral bioavailability, Int. J. Pharm. 149 (1997) 73-83.
54. F. Hirayama, Z. Wang, K. Uekama, Effect of 2-hydroxypropyl-β-cyclodextrin on crystallization and polymorphic transition of nifedipine in solid state, Pharm. Res. 11 (1994) 1766-1770.
55. J. Pitha, S.M. Harman, M.E. Michel, Hydrophilic cyclodextrin derivatives enable effective oral administration of steroidal hormones, J. Pharm. Sci. 75 (1986) 165-167.
56. J. Pitha, E.J. Anaissie, K. Uekama, γ-Cyclodextrin: testosterone complex suitable for sublingual administration, J. Pharm. Sci. 76 (1987) 788-790.
57. G.T. Tayler, J. Weiss, J. Pitha, Testosterone in a cyclodextrin containing formulation: behavioral and physiological effects of episode-like pulses in rats, Pharm. Res. 6 (1989) 641-646.
58. C.A. Stuenkel, R.E. Dudley, S.S. Yen, Sublingual administration of testosterone-hydroxypropyl-β-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men, J. Clin. Endocrinol. Metab. 72 (1991) 1054-1059.
59. B. Salehian, C. Wang, G. Alexander, T. Davidson, V. McDonald, N. Berman, R.E. Dudley, F. Ziel, R.S. Swerdloff, Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate, J. Clin. Endocrinol. Metab. 80 (1995) 2567-3575.
60. H. Fridriksdottir, T. Loftsson, J.A. Gudmundsson, G.J. Bjarnason, M. Kjeld, T. Thorsteinsson, Design and in vivo testing of 17β-estradiol- hydroxypropyl-β-cyclodextrin sublingual tablets, Pharmazie 51 (1996) 39-42.
61. H. Seo, K. Uekama, Enhanced bioavailability of digoxin by γ-cyclodextrin complexation: evaluation for sublingual and oral administrations in human, Yakugaku Zasshi 109 (1989) 778-782.
62. M. Skiba, C. Morvan, D. Duchêne, F. Puisieux, D. Wouessidjewe, Evaluation of gastrointestinal behavior in the rat of amphiphilic β-cyclodextrin nanocapsules, loaded with indomethacin, Int. J. Pharm. 126 (1995) 275-279.
63. K. Uekama, T. Horikawa, Y. Horiuchi, F. Hirayama, In vitro and in vivo evaluation of delayed-release behavior of diltiazem from its O-carboxymethyl-O-ethyl-β-cyclodextrin complex, J. Control. Release 25 (1993) 99-106.
64. T. Horikawa, F. Hirayama, K. Uekama, In-vivo and in-vitro correlation for delayed-release behavior of a molsidomine/ O-carboxymethyl-O-ethyl-β-cyclodextrin complex in gastric acidity-controlled dogs, J. Pharm. Pharmacol. 47 (1995) 124-127.
65. Y. Horiuchi, F. Hirayama, K. Uekama, Slow-release characteristics of diltiazem from ethylated β-cyclodextrin complexes, J. Pharm. Sci. 79 (1990) 128-132.
66. F. Hirayama, N. Hirashima, K. Abe, K. Uekama, T. Ijitsu, M. Ueno, Utilization of diethyl-β-cyclodextrin as a sustained-release carrier for isosorbide dinitrate, J. Pharm. Sci. 77 (1989) 233-236.
67. K. Nakanishi, T. Masukawa, T. Nadai, K. Yoshii, S. Okada, K. Miyajima, Sustained-release of flufenamic acid from a drug-triacetyl-β-cyclodextrin complex, Biol. Pharm. Bull. 20 (1997) 66-70.
68. M. Yamada, F. Hirayama, K. Uekama, Release-control of a water-soluble drug by film-forming trivaleryl-β-cyclodextrin, Drug Delivery System, 14, in press.
69. K. Uekama, T. Horikawa, M. Yamanaka, F. Hirayama, Peracylated β-cyclodextrins as novel sustained-release carriers for a water-soluble drug, molsidomine, J. Pharm. Pharmacol. 46 (1994) 714-717.
70. F. Hirayama, T. Horikawa, M. Yamanaka, K. Uekama, Enhanced bioavailability and reduced metabolism of salbutamol by perbutanoyl-β-cyclodextrin after oral administration in dogs, Pharm. Sci. 1 (1995) 517-520.
71. O.A. Soliman, K. Kimura, F. Hirayama, K. Uekama, H.M. El-Sabbagh, A.H. Abd ElGawad, F.M. Hashim, Controlled release of diltiazem by a combination of short- and long-chain peracylated-β-cyclodextrins in dogs, Pharm. Sci. 2 (1996) 533-536.
72. K. Uekama, K. Ikegami, Z. Wang, Y. Horiuchi, F. Hirayama, Inhibitory effect of 2-hydroxypropyl-β-cyclodextrin on crystal-growth of nifedipine during storage: superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30, J. Pharm. Pharmacol. 44 (1992) 73-78.
73. Z. Wang, K. Ikegami, F. Hirayama, K. Uekama, Release characteristics of nifedipine from 2-hydroxypropyl-β-cyclodextrin complex during storage and its modification of hybridizing polyvinylpyrrolidone K-30, Chem. Pharm. Bull. 41 (1993) 1822-1826.
74. Z. Wang, F. Hirayama, K. Uekama, Design and in-vitro evaluation of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-β-cyclodextrin and hydroxypropyl cellulose, J. Pharm. Pharmacol. 45 (1993) 942-946.
75. Z. Wang, F. Hirayama, K. Uekama, In-vivo and in-vitro evaluations of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-β-cyclodextrin and hydroxypropyl celluloses in dogs, J. Pharm. Pharmacol. 46 (1994) 505-507.
76. K. Uekama, K. Matsubara, K. Abe, Y. Horiuchi, F. Hirayama, N. Suzuki, Design and in vitro evaluation of slow-release dosage form of piretanide: utility of β-cyclodextrin/cellulose derivative combination as a modified-release drug carrier, J. Pharm. Sci. 79 (1990) 244-248.
77. G.M. Zentner, G.S. Rork, K.J. Himmelstein, Osmotic flow through controlled porosity films: an approach to delivery of water-soluble compounds, J. Control. Release 2 (1989) 217-229.
78. 7m-β-cyclodextrin. Pharm. Res. in press.
79. K. Okimoto, R.A. Rajewski, K. Uekama, J.A. Jana, V.J. Stella, The interaction of charged and uncharged drugs with neutral (HB-β-CD) and anionically charged (SBE-β-CD) β-cyclodextrins, Pharm. Res. 13 (1996) 256-264.
80. 7m-β-cyclodextrin, in: Abstracts of the 9th International Symposium on Cyclodextrins, Santiago de Compostela, 1998, pp. 3-15.
81. N. Bodor, Redox drug delivery systems for targeting drugs to the brain, Ann. NY Acad. Sci. 507 (1987) 289-306.
82. D.R. Friend (Ed.), Oral Colon-specific Drug Delivery, CRC Press, Boca Raton, FL, 1992.
83. L. Hovgaad, H. Broendsted, Current applications of polysaccharides in colon targeting, CRC Crit. Rev. Ther. Drug Carrier Syst. 13 (1996) 185-223.
84. F. Hirayama, K. Minami, K. Uekama, In-vitro evaluation of biphenylylacetic acid-β-cyclodextrin conjugates as colon-targeting prodrugs: drug release behavior in rat biological media, J. Pharm. Pharmacol. 48 (1996) 27-31.
85. K. Minami, F. Hirayama, K. Uekama, Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration, J. Pharm. Sci. 87 (1998) 715-720.
86. D.J. Begley, The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system, J. Pharm. Pharmacol. 48 (1996) 136-146.
87. N. Bodor, Prodrugs versus soft drugs, in: H. Bundgaard (Ed.), Design of Prodrugs. Elsevier, Amsterdam, 1985, Ch. 11, pp. 333-354.
88. M.E. Brewster, K. Estes, T. Loftsson, R. Perchalski, H. Derendorf, G. Mullersman, N. Bodor, Improved delivery through biological membranes. XXXI: solubilization and stabilization of an estradiol chemical delivery system by modified β-cyclodextrins, J. Pharm. Sci. 77 (1988) 981-985.
89. W.R. Anderson, J.W. Simpkins, M.E. Brewster, N. Bodor, Brain-enhanced delivery of testosterone using a chemical delivery system complexed with 2-hydoxypropyl-β-cyclodextrin, Drug Design Deliv. 2 (1988) 287-298.
90. E. Pop, T. Loftsson, N. Bodor, Solubilization and stabilization of a benzylpenicillin chemical delivery system by 2-hydroxypropyl-β-cyclodextrin, Pharm. Res. 8 (1991) 1044-1049.
91. T. Siegal, F. Soti, A. Biegon, E. Pop, M.E. Brewster, Effect of a chemical delivery system for dexamethasone (Dex-CDS) on peritumoral edema in an experimental brain tumor model, Pharm. Res. 14 (1997) 672-675.
92. F. Djedaini-Pilard, J. Désalos, B. Perly, Synthesis of a new carrier: N(Leu-enkephalin)yl-6-amino-6-deoxy-cyclomaltoheptaose, Tetrahedron Lett. 34 (1993) 2457-2460.
93. M.K. Hristova-Kazmierski, P. Horan, P. Davis, H.I. Yamamura, T. Kramer, R. Horvath, W.M. Kazmierski, F. Porreca, V. Hruby, A new approach to enhance bioavailability of biologically active peptides: conjugation of a 5 opioid agonist to β-cyclodextrin, Bioorg. Med. Chem. Lett. 3 (1993) 831-834.
94. D. Gottlieb, P.D. Shaw (Ed.), Antibiotics. I. Mechanism of Action. Springer-Verlag, Berlin, 1967.
95. D.N. Karunaratne, S. Farmer, R.E.W. Hancock, Synthesis of bulky β-lactams for inhibition of cell surface β-lactamase activity, Bioconjugate Chem. 4 (1993) 434-439.
96. C. Kim, W.C. MacKellar, N. Cho, S.R. Byrn, D.J. Morre, Impermeant antitumor sulfonylurea conjugates that inhibit plasma membrane NADH oxidase and growth of HeLa cells in culture: identification of binding proteins from sera of cancer patients, Biochim. Biophys. Acta 1324 (1997) 171-181.
97. B. Alberts, D. Bray, J. Lewis, M. Raff, K. Roberts, J.D. Watson (Ed.), Molecular Biology of the Cell, third ed., Garland Publishing, New York, 1994.
98. H. Parrot-Lopez, E. Leray, A.W. Coleman, New β-cyclodextrin derivatives possessing biologically active saccharide antennae, Supramol. Chem. 3 (1993) 37-42.
99. L. Robertis, C. Lancelon-Pin, H. Driguez, F. Attioui, R. Bonaly, A. Marsura, Synthesis of new oligosaccharidyl-thio-β-cyclodextrins (CDS): a novel family of potent drug-targeting vectors, Bioorg. Med. Chem. Lett. 4 (1994) 1127-1130.
100. E. Leray, H. Parrot-Lopez, C. Auge, A.W. Coleman, C. Finance, R. Bonaly, Chemical-enzymatic synthesis and bioactivity of mono-6-[gal-β-1,4-glcNAc-β-(1,6′)-hexyl]amido-6-deoxy- cycloheptaamylose. J. Chem. Soc. Chem. Commun. (1995) 1019-1020.
101. H. Imata, K. Kubota, K. Hattori, M. Aoyagi, C. Jindoh, The specificity of association between concanavalin A and oligosaccharide-branched cyclodextrins with an optical biosensor, Bioorg. Med. Chem. Lett. 7 (1997) 109-112.
102. F. Attioui, A. Al-Omar, E. Leray, H. Parrot-Lopez, C. Finance, R. Bonaly, Recognition ability and cytotoxicity of some oligosaccharidyl substituted β-cyclodextrins, Biol. Cell 82 (1994) 161-167.
103. I. Habus, Q. Zhao, S. Agrawal, Synthesis, hybridization properties, nuclease stability, and cellular uptake of the oligonucleotide-amino-β-cyclodextrins and adamantane conjugates, Bioconjugate Chem. 6 (1995) 327-331.
104. H. Tanaka, K. Kominato, R. Yamamoto, T. Yoshioka, H. Nishida, H. Tone, R. Okamoto, Synthesis of doxorubicin-cyclodextrin conjugates, J. Antibiot. 47 (1994) 1025-1029.
105. C. Péan, A. Wijkhuisen, F. Djedaini-Pilard, C. Créminon, J. Grassi, B. Perly, Pharmacological investigations of new peptide-cyclodextrins, in: Abstracts of the 9th International Symposium on Cyclodextrins, Santiago de Compostela, 1998, p. 3-P-43.
106. C. Péan, J. Fische, A. Wijkhuisen, F. Djedaini-Pilard, C. Créminon, B. Perly, M. Conrath, In vitro and in vivo investigation of the specific binding of substance P-γ-cyclodextrin adduct (SB-γ-CD) to rat brain NK1 receptors, in: Abstracts of the 9th International Symposium on Cyclodextrins, Santiago de Compostela, 1998, p. 3-P-56.
107. N. Schaschke, S. Fiori, E. Weyher, C. Escrieut, D. Fourmy, G. Muller, L. Moroder, Cyclodextrin as carrier of peptide hormones: conformational and biological properties of β-cyclodextrin/gastrin constructs, J. Am. Chem. Soc. 120 (1998) 7030-7038.